FDA Warning Letters Flag Five Peptide Vendors' Unapproved GLP-1s

The U.S. Food and Drug Administration has put five online peptide vendors on notice for selling unapproved drugs — including the GLP-1 peptides semaglutide, tirzepatide, and retatrutide — behind “research use only” disclaimers. In warning letters dated August 24 and posted publicly this week, the agency said website evidence shows the products were intended for human use and gave the companies 15 business days to respond.

The five recipients are Peak Performance Peptides (Phoenix), Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC, which does business as Tex Peptides (Dallas). The letters, issued by the Center for Drug Evaluation and Research, document FDA reviews of each company’s website and identify products the agency considers unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act.

Read the full buyer explainer: FDA Warns Online Peptide Sellers: What the Crackdown Means for Buyers — how to verify a legitimate source, what the letters mean for you, and where Category 2 and the no-compounding list fit.

Product lists vary by vendor. The letter to Tex Peptides cites semaglutide, tirzepatide, retatrutide, SS-31 (elamipretide), tesamorelin, PT-141 (bremelanotide), and bacteriostatic water. The letter to Peak Performance Peptides cites retatrutide, semaglutide, SS-31, PT-141, tesamorelin, and “bac water.” FDA states that introducing or delivering the products into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.

FDA Rejects the “Research Use Only” Defense

The letters open with standard enforcement language: “This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website.” They also stress the risk profile of the category: “These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users.”

The passage with the widest implications for the research-peptide market is a footnote addressing product labeling that says “research use only” or “not for human or veterinary use.” FDA wrote: “evidence obtained from your website establishes that your products are intended to be drugs for human use.” The letter adds that marketing bacteriostatic water “as a solvent for reconstituting your products” provides “the means to prepare an injectable drug for human administration.”

The list spans molecules with very different histories — semaglutide and tirzepatide have FDA-approved versions on the market, while retatrutide and SS-31 (elamipretide) do not — but the letters sidestep those distinctions. As the Tex Peptides letter states, “[n]o approved applications pursuant to section 505 of the FD&C Act … are in effect for these products,” which is what makes them unapproved new drugs as sold, regardless of how the products are labeled. Retatrutide is the sharper case: despite positive topline results across all four core TRIUMPH Phase 3 trials — see our retatrutide Phase 3 results and availability timeline — it is not just unapproved, it cannot lawfully be compounded by any pharmacy — the FDA told state boards in March 2025 that it fails every 503A/503B test — which is why the September state-board enforcement push matters (legality explainer). The BBC documented the resulting black market — how to spot counterfeit retatrutide.

Enforcement Broadens Beyond Compounding

The action widens an FDA crackdown that began this year with licensed telehealth prescribers and compounding pharmacies. In March, the agency sent warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 drugs. The new letters target a different tier of the market: web-native vendors that sell vials and reconstitution supplies directly to consumers, outside the compounding regulatory framework — the segment PeptidesBeat examined after the April 15 bulk-substance decision.

FDA’s concern is not only legal. Unapproved injectable peptides have been linked to contaminated-product cases with severe outcomes, and counterfeit retatrutide has been tied to liver toxicity reports in Australia. Around the time the letters were published, FDA’s consumer fact sheet on unapproved GLP-1 drugs used for weight loss added a section on concerns with multi-dose vials, according to trade publication pharmaphorum.

What Happens Next

Under the letters, each company has 15 business days from receipt to respond in writing with the specific steps taken to correct the violations and prevent their recurrence. FDA warns that failure to “adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.” The letters were delivered by email, and the response window closes around mid-September.

The practical significance extends beyond the five named vendors. The letters put every business selling unapproved injectable peptides under research-use labeling on notice that FDA evaluates websites in context — and that disclaimers alone are unlikely to shield them from enforcement.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.